119-hr1796

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1796 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
 H. R. 1796

 To amend the Public Health Service Act to reauthorize a sickle cell 
 disease prevention and treatment demonstration program.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 March 3, 2025

Mr. James (for himself, Mr. Veasey, Mr. Carter of Louisiana, Mr. Davis 
 of Illinois, and Mrs. Kiggans of Virginia) introduced the following 
 bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

 A BILL

 To amend the Public Health Service Act to reauthorize a sickle cell 
 disease prevention and treatment demonstration program.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``Sickle Cell Disease and Other 
Heritable Blood Disorders Research, Surveillance, Prevention, and 
Treatment Act of 2025''.

SEC. 2. SICKLE CELL DISEASE TREATMENT PREVENTION AND TREATMENT.

    (a) In General.--

Section 1106

    (b) of the Public Health Service Act 
(42 U.S.C. 300b-5

    (b) ) is amended--

    (1) in paragraph

    (1)
        (A)
            (iii) , by striking ``prevention and 
 treatment of sickle cell disease'' and inserting ``treatment of 
 sickle cell disease and the prevention and treatment of 
 complications of sickle cell disease'';

    (2) in paragraph

    (2)
            (D) , by striking ``prevention and 
 treatment of sickle cell disease'' and inserting ``treatment of 
 sickle cell disease and the prevention and treatment of 
 complications of sickle cell disease'';

    (3) in paragraph

    (3) --
        (A) in subparagraph
        (A) , by striking ``enter into a 
 contract with'' and inserting ``make a grant to, or 
 enter into a contract or cooperative agreement with,''; 
 and
        (B) in subparagraph
        (B) , in each of clauses
            (ii) and
            (iii) , by striking ``prevention and treatment of 
 sickle cell disease'' and inserting ``treatment of 
 sickle cell disease and the prevention and treatment of 
 complications of sickle cell disease''; and

    (4) in paragraph

    (6) , by striking ``$4,455,000 for each of 
 fiscal years 2019 through 2023'' and inserting ``$8,205,000 for 
 each of fiscal years 2025 through 2029''.

    (b) Sense of Congress.--It is the sense of Congress that further 
research should be undertaken to expand the understanding of the causes 
of, and to find cures for, heritable blood disorders, including sickle 
cell disease.
 <all>